Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against Trypanosoma cruzi
Chagas disease caused by the protozoan parasite Trypanosoma cruzi is endemic in 21 Latin American countries and the southern United States and now is spreading into several other countries due to migration. Despite the efforts to control the vector throughout the Americas, currently, there are almos...
Main Authors: | Natacha Cerny, Augusto Ernesto Bivona, Andrés Sanchez Alberti, Sebastián Nicolás Trinitario, Celina Morales, Alejandro Cardoso Landaburu, Silvia Inés Cazorla, Emilio Luis Malchiodi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.565142/full |
Similar Items
-
In Silico Analysis of Homologous Heterodimers of Cruzipain-Chagasin from Structural Models Built by Homology
by: Francisco Reyes-Espinosa, et al.
Published: (2019-03-01) -
Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection
by: María Belén Antonoglou, et al.
Published: (2020-06-01) -
Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi
by: Andrés Sanchez Alberti, et al.
Published: (2020-02-01) -
Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
by: Augusto E Bivona, et al.
Published: (2018-03-01) -
Lopinavir and Nelfinavir Induce the Accumulation of Crystalloid Lipid Inclusions within the Reservosomes of <i>Trypanosoma cruzi</i> and Inhibit Both Aspartyl-Type Peptidase and Cruzipain Activities Detected in These Crucial Organelles
by: Leandro S. Sangenito, et al.
Published: (2021-07-01)